Pembrolizumab failure stems from SARC028, the first prospective open-label phase II multicenter study where none of the thirteen enrolled ES patients showed any clinical benefit from anti-PD-1 blockade [99]. This evidence concerns the gene PDCD1 and Ewing sarcoma.